Market capitalization | $173.44m |
Enterprise Value | $170.96m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | negative |
Turnover (TTM) Turnover | $0.00 |
EBIT (operating result TTM) EBIT | $-59.86m |
Free cash flow (TTM) Free cash flow | $-58.26m |
Cash position | $47.23m |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
7 Analysts have issued a Outlook Therapeutics, Inc. forecast:
7 Analysts have issued a Outlook Therapeutics, Inc. forecast:
Mar '24 |
+/-
%
|
||
Net profit | -114 -114 |
1,619%
1,619%
|
|
Depreciation and amortization | 0.03 0.03 |
200%
200%
|
|
Share compensation | 1.31 1.31 |
5%
5%
|
|
Operating cash flow | -19 -19 |
138%
138%
|
|
Investments | - - |
-
|
|
Dividend paid | - - |
-
|
|
Free cash flow | -19 -19 |
138%
138%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the identification, development, manufacture, and commercialization of complex biosimilar therapeutics. It focuses on monoclonal antibodies, in the disease areas of immunology and oncology. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Cranbury, NJ.
Head office | United States |
CEO | C. Trenary |
Employees | 24 |
Founded | 2010 |
Website | www.outlooktherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.